HALO Royalty Surge 45.8% in 9M26 Bolsters Growth but Valuation Concerns Persist

What happened

Halozyme reported a 45.8% year-over-year surge in royalty revenues for the first nine months of 2026, prompting management to raise full-year guidance. This acceleration builds on the 2025 performance where royalties reached $571 million and total revenue $1.02 billion, and reflects rapid adoption of ENHANZE-enabled products like DARZALEX SC, Phesgo, VYVGART Hytrulo, and newer launches such as TECENTRIQ SC and OCREVUS SC. The news validates the strong demand for subcutaneous biologics and Halozyme's platform economics, but it does not alter the previously identified structural risks including the 2027 IP cliff, high partner concentration, and leveraged M&A strategy. The stock, which closed at $65.77 in December 2025 and was already trading about 33% above a DCF estimate of $49.46, likely edged higher on the announcement, further extending its premium. Overall, the royalty momentum is positive but the market may be underappreciating the medium-term uncertainties that still cloud the investment case.

Implication

The sharp royalty increase and raised guidance strengthen confidence in Halozyme's near-term cash flow generation, potentially supporting the current share price and providing downside cushion if broad market conditions weaken. However, the core ENHANZE patents begin expiring in 2027, and although partner formulation and device patents may extend some royalties into the 2030s, the economic terms for key products like DARZALEX SC could step down materially, creating a cliff risk that the market may not fully price. High customer concentration remains a concern: one partner accounted for 41% of 2024 revenue and two partners together represented 58%, so any shift in partner strategy or biosimilar competition could disproportionately impact results. The company's aggressive M&A (Antares, Elektrofi, potential Evotec) and ~$1.5B debt with 2027-2028 maturities add execution and refinancing risk that is not fully offset by the royalty growth, especially if interest rates stay elevated or integration stumbles. Therefore, while the royalty trajectory is impressive, investors should monitor IP litigation outcomes, partner product uptake trends, and leverage reduction progress; until the post-2027 earnings power becomes clearer, the risk/reward balance favors patience over chasing the stock higher.

Thesis delta

The royalty surge and higher guidance modestly improve the near-term fundamentals and support the thesis that ENHANZE remains in high demand, but they do not address the core concerns that underpinned the prior WAIT rating: valuation stretched ~33% above DCF, IP expiry in 2027, high partner concentration, and leveraged M&A. The update may push the stock further above intrinsic value, making the margin of safety even thinner, but without evidence of partner durability beyond 2027 or deleveraging progress, the overall risk/reward remains balanced. Thus, the rating remains WAIT, with the positive data serving as a confirmation of current strength rather than a catalyst for a fundamental re-rating.